ginkgolide b has been researched along with Gram-Negative Bacterial Infections in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dhainaut, JF; Dreyfuss, D; Holzapfel, L; Le Tulzo, Y; Mira, JP; Schlemmer, B; Solet, JP; Tenaillon, A; Wolff, M; Zeni, F | 1 |
| Damas, P; de Vathaire, F; Dhainaut, JF; Gourlay, ML; Guinot, P; Hemmer, M; Holzapfel, L; Le Tulzo, Y; Mira, JP; Radermacher, P; Schaller, MD; Sollet, JP; Tenaillon, A; Vedrinne, JM; Wolff, M; Zeni, F | 1 |
2 trial(s) available for ginkgolide b and Gram-Negative Bacterial Infections
| Article | Year |
|---|---|
Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group.
Topics: Adult; Aged; APACHE; Diterpenes; Double-Blind Method; France; Ginkgolides; Gram-Negative Bacterial Infections; Humans; Lactones; Middle Aged; Placebos; Platelet Activating Factor; Prognosis; Statistics as Topic; Systemic Inflammatory Response Syndrome | 1994 |
Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group.
Topics: Adult; Aged; Analysis of Variance; APACHE; Diterpenes; Double-Blind Method; Free Radical Scavengers; Ginkgolides; Gram-Negative Bacterial Infections; Humans; Lactones; Middle Aged; Platelet Activating Factor; Prospective Studies; Sepsis; Survival Analysis | 1998 |